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A B S T R A C T
Objective: Depression is a frequent psychiatric disorder in children with temporal lobe epilepsy (TLE).
However, severity of depressive symptoms (DS) is frequently neglected in these patients. This study
aimed to determine severity of DS and global functioning by using quantitative measures and to
establish their correlation with patients’ demographics and clinical variables.
Methods: 31 children (mean age of 11.8  2.3 years) with TLE were assessed with K-SADS-PL for axis I DSM-
IV diagnosis. Severity of DS was measured by Children Depression Rating Scale-Revised – CDRS-R. Global
functional impairment was evaluated with Child Global Assessment Scale-CGAS.
Results: 25 patients (56% boys; 12  2.3 years) had current DS, moderate or severe in 84% according to
CDRS-R T-Score. Severity of DS was not correlated with age (p = 0.377), gender (p = 0.132), seizure control
(p = 0.936), age of onset (p = 0.731), duration of epilepsy (p = 0.602) and the presence of hippocampal
sclerosis (p = 0.614). Patients had moderate to major functional impairment measured by CGAS (48.7  8.8),
being adolescents more impaired than children (p = 0.03). Impairment of global functioning was not
associated with epilepsy variables (p > 0.05).
Conclusion: Children with TLE had moderate to severe DS early in the course of their disease with a
relevant impact on their global functional activities, especially considering adolescents. Epilepsy
severity seems not to be correlated to the severity of DS, contradicting the idea of a cause–consequence
relationship. More systematic research is needed to better understand the association of depressive
disorders in children and adolescents with TLE.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The prevalence of psychiatric disorders (PD) in persons with
epilepsy is high compared to general population. Mood disorders
occur in 11 to 62%; psychosis in 7 to 10% and personality disorders
in 5 to 33%.1–6 Depression is the most frequent PD in persons with
epilepsy.7–9
It is assumed that the rate of depression ranges from 20 to 55%
in patients with refractory epilepsy, especially considering those
with temporal lobe epilepsy caused by mesial temporal sclerosis
(MTLE). Furthermore, people with epilepsy have a lifetime
prevalence of any type of mood disorder higher than that observed§ Dr. Valente is funded by CNPq 307262/2011-1 and FAPESP 05/56464-9; 06/
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http://dx.doi.org/10.1016/j.seizure.2013.05.008in general population or people with other chronic medical
disorders. Despite its high prevalence, depression remains under-
diagnosed and undertreated in persons with epilepsy, with
relevant personal and social costs.10
Depression has also been described as a common comorbidity
in children and adolescents with epilepsy.1,11–14 The presence of
depressive symptoms in pediatric population favors the idea of a
common pathogenic mechanisms, contradicting the previous
concept of depression as a consequence of longer epilepsy
duration.
The impact of depression severity in morbidity can be evaluated
by some studies of quality of life in patients with refractory
epilepsy (9.7 seizures/month; mean duration of epilepsy of 12.7
years).9,15 Quality of life (QOLIE-89) summary score was signiﬁ-
cantly associated with depression scales, but not with the type and
or the frequency of seizures, although patients averaged 0.3–
51 seizures/month.15 However, studies in children and adolescents
with epilepsy and depression frequently neglect depression
severity. It is well-known that different degrees of DS severityvier Ltd. All rights reserved.
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ing,16 especially in children.
We believe that children and adolescents with TLE may present
high rates of moderated and severe depressive symptoms (DS)
early in the course of their illness with important impairment on
their global functioning. This descriptive cross-sectional study
aimed to: (i) determine severity of DS by using a quantitative
measure (CDRS-R) and (ii) investigate whether these patients




Patients enrolled in this study had focal epilepsy and were
referred from primary and tertiary centers.
After neurological evaluation, 31 children and adolescents
(11.8  2.3 years-old; 56% male) with TLE were invited to participate
in the present study.
Inclusion criteria were clinical diagnosis of TLE corroborated by
EEG and/or video-EEG and neuroimaging study by 3 Tesla MRI.
Epilepsy was classiﬁed according to International League Against
Epilepsy (ILAE 2001) criteria as symptomatic and probably
symptomatic. Patients with symptomatic epilepsy were evaluated
and categorized according to their lesion and location (mesial and
lateral). Patients with probably symptomatic TLE were determined
by ictal video/EEG and concordant interictal EEG ﬁndings. Patients
with extratemporal epileptiform activity were excluded.
Exclusion criteria were the presence of other chronic medical
illness than epilepsy; previous neurosurgery; history of substance
and/or alcohol abuse or dependence; pervasive developmental
disorder; schizophrenia and severe psychotic disorder.
Patients had neuropsychological evaluation using Block Design
and Vocabulary subtests of the Wechsler Intelligence Scale for
Children, Third Edition (WISC-III) 20. The mean estimated
Intelligence Quotient (IQ) was 102.1 (range: 85–135; SD = 14.9).
Patients with moderate to severe mental retardation during
determined by the child neurologist during neurological evalua-
tion were excluded.
Local ethics committee approved this study and before initial
evaluation, we obtained the signed consent from the parent or
legal guardians in accordance with the institutional review boards
at University of Sao Paulo, Brazil.
2.2. Psychiatric evaluation and procedure
The psychiatric evaluation used in this study involved four
stages with distinct instruments that will be described as follow:
2.2.1. Assessment of DS
2.2.1.1 Psychiatric Interview: After consent and assent were
obtained, parents were interviewed about their children.
Children and adolescents were directly interviewed for a
clinical diagnosis and classiﬁed according to DSM-IV TR
criteria by a child and adolescent psychiatrist. Patients
were scheduled for a second interview with KSADS-PL no
more than 6 weeks later.
2.2.1.2 KSADS-PL: Patient were evaluated by a Portuguese
validated version of Schedule for Affective Disorders and
Schizophrenia for School Aged-Children – KSADS-PL17
(Kaufman et al., 1996) and diagnosed according to DSM-
IV axis-I. Presence of DS was assessed by the Mood
Disorders Supplement of KSADS-PL.2.2.2. Severity of depressive symptoms
2.2.2.1 Children Depression Rating Scale-Revised – CDRS-R18
(Poznanski et al., 1996) is a semi-structured interview
which rate 17 symptom areas: impaired schoolwork,
difﬁculty having fun, social withdrawal, appetite
disturbance, sleep disturbance, excessive fatigue, phys-
ical complaints, irritability, excessive guilt, low self-
esteem, depressed feelings, morbid ideas, suicidal
ideas, excessive weeping, depressed facial affect,
listless speech, and hypoactivity. The CDRS-R T-Score
measures the clinical signiﬁcance of symptom ratings
categorized as non-depressed (0–54), mild (55–64),
moderated (65–74) and severe (75) and was used to
evaluate the severity of DS.
2.2.2.2 Child Global Assessment Scale – CGAS19 (Shaffer et al.,
1983) was used to assess functional impairment in the last
month. It is an instrument to measure overall severity of the
psychiatric disorder and measurement of global function-
ing impairment, and is of heuristic value to complement
other methods of diagnostic categorization. This measure
provides a single global rating on scale of 0–100. Patients
are classiﬁed as follow: (1) 100–91: Superior functioning in
all areas (at home, at school and with peers); involved in a
wide range of activities and has many interests; (2) 90–81:
Good functioning in all areas; secure in family, school, and
with peers; there may be transient difﬁculties and
‘everyday’ worries that occasionally get out of hand; (3)
80–71: No more than slight impairments in functioning at
home, at school, or with peers; some disturbance of
behavior or emotional distress may be present in response
to life stresses, but these are brief and interference with
functioning is transient; (4) 70–61: Some difﬁculty in a
single area but generally functioning pretty well (e.g.
sporadic or isolated antisocial acts, such as occasionally
playing hooky or petty theft; consistent minor difﬁculties
with school); (5) 60–51: Variable functioning with sporadic
difﬁculties or symptoms in several but not all social areas;
(6) 50–41: Moderate degree of interference in functioning
in most social areas or sever impairment of functioning in
one area, such as might result from, for example, school
refusal; (7) 40–31: Major impairment of functioning in
several areas and unable to function in one of these areas (at
home, at school, with peers); (8) 30–21: Unable to function
in almost all areas; (9) 20–11: Needs considerable
supervision to prevent hurting others or self or to maintain
personal; and (10) 10–1: Needs constant supervision (24-h
care) due to severely aggressive or self-destructive behav-
ior or gross impairment in reality testing, communication,
cognition, affect or personal hygiene.
2.2.3. Correlation between patients’ demographics and clinical
variables with DS severity
Patient-related factors such as age (grouped according to
Piaget’s cognitive scale: <6 years, 7–13 years, >13 years) and
gender were analyzed.
Epilepsy variables such as age of onset, duration, seizure
control, seizure frequency, refractoriness, antiepileptic drugs
(mono- vs polytherapy), seizure type (generalized vs focal),
presence of mesial temporal sclerosis and laterality were
determined by two epileptologists. These variables were
correlated with the severity determined by CDRS-S and CGAS.
Table 1
Demographics and clinical characteristics.
ID Age years Gender Location Laterality Age of onset years Duration years Refractoriness AED Surgery
1 12 F Mesial Bil > left 2 10 P Polytherapy OXC/CLB
2 13 F Mesial Right 5 9 P Polytherapy CBZ/CLB P
3 11 M Lateral Right 2 11 P Polytherapy CBZ/CLB
4 8 F Lateral Left 7 1 P Polytherapy CBZ/CLB
5 16 M Mesial Left 1 15 P Polytherapy CBZ/TPM P
6 11 M Mesial Left 1 9 P Polytherapy CBZ/CLB P
7 15 F Mesial Right 7 8 A Polytherapy VPA/LTG
8 13 M Mesial Right 1 12 A Monotherapy OXC
9 13 F Mesial Left 7 3 A Monotherapy CBZ
10 12 M Lateral Right 2 11 A Polytherapy CBZ/CLB
11 12 M Lateral Right 9 2 A Monotherapy OXC
12 12 F Mesial Bil > right 10 2 P Polytherapy OXC/CLB
13 15 F Lateral Right 1 12 A Monotherapy OXC
14 15 F Lateral Right 7 8 P Polytherapy OXC/CLB
15 8 F Lateral Right 5 3 P Polytherapy CBZ/CLB
16 17 M Lateral Left 4 13 P Polytherapy OXC/CLB
17 11 M Mesial Left 3 8 P Polytherapy CBZ/CLB
18 13 M Mesial Left 13 0.14 P Polytherapy CBZ/CLB
19 08 M Mesial Right 3 4 A Monotherapy CBZ
20 09 F Mesial Right 2 7 A Monotherapy CBZ
21 10 M Mesial Right 2 4 A Monotherapy CBZ
22 09 M Lateral Left 3 6 P Polytherapy CBZ/CLB
23 12 M Lateral Left 11 1 A Monotherapy VPA
24 15 M Lateral Left 9 3 A Monotherapy CBZ
25 10 F Lateral Bil > left 10 1 A Monotherapy CBZ
Table 2
DS characteristics of the studied sample (N = 25).
Age at onset of DS; mean (SD), years 8.3 (2.9 years)
Time of duration of DS, years 3.4 (2.4 years)
Severity of DS; mean (SD) CDRS-R 70 (7.3)
Global functioning; mean (SD) CGAS 48.8 (8.9)
DSM-V TR criteria for depressive disorders 48%
MDD 25%
Dysthymia 75%
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Statistical analysis was performed by descriptive statistic tests:
t-test, Person Chi-Square and Pearson correlation for correlation
between DS severity and epilepsy variables. All analyses were
performed through Statistical Package for the Social Sciences
Version 10 (SPSS).
3. Results
Twenty-ﬁve (80.6%) patients with TLE, 14 boys (56%) with a
mean age of 12 years (SD = 2.27) had current DS.
The mean age of epilepsy onset was 5.1 years (SD = 3.7).
Children and adolescents with TLE had a mean time of epilepsy
duration of 6.5 years (SD = 4.2). Thirteen patients (56%) had
refractory epilepsy and three (12%) out of these were submitted to
epilepsy surgery. Eleven (44%) patients were in monotherapy.
Twelve patients (48%) had well-controlled epilepsy at the time of
this evaluation. The criterion for seizure control in these 18
patients was at least 6 months of seizure freedom prior to this
assessment. Ten patients (40%) were on monotherapy, 15 (60%)
were on polytherapy. Seventeen patients (68%) had symptomatic
TLE, 13 (52%) with mesial temporal sclerosis. In the lateral group,
two had tumor (DNET), one presented with a focal cortical
dysplasia, and one with gliosis. We also included eight patients
(32%) with probably symptomatic TLE determined by ictal video/
EEG and concordant interictal EEG ﬁndings. Patients with
extratemporal epileptiform activity were excluded. The demo-
graphics and clinical characteristics of these patients are demon-
strated in Table 1.
Out of these 25 patients, 12 (48%) patients presented with
depressive disorder according to DSM-IV criteria (nine with
dysthymia and three with major depressive disorder). The mean
age of onset of DS was 8.3 years (SD = 2.9) and the mean time of
duration of DS was 3.4 years (SD = 2.4) (Table 2).
Depressive symptoms were diagnosed in most of these children
and adolescents with TLE (76%) at the time of psychiatric
assessment for this study. Interval between the emergence of
DS and the diagnosis was 3.6 years (SD = 2.3).Five (20%) patients had the onset of DS concomitant with the
ﬁrst seizure and 18 (72%) after epilepsy onset. Two (8%) patients
had the onset of DS before the ﬁrst seizure, according to parents
report. In those patients with DS after the ﬁst seizure, mean
interval between the epilepsy onset and the emergence of DS was
4.3 years (SD = 3.7).
Six patients (24%) had other psychiatric comorbidities, three
(12%) with ADHD and three (12%) with anxiety disorder.
3.1. Severity of DS
CDRS-R T-Score: DS were considered mild in 4 (16%), moderate
in 11 (44%) and severe in 10 (40%) patients, according to CDRS-R
T-Score (Table 2). There was no difference in severity of DS
between age (p = 0.377) and gender group comparison
(p = 0.132).
CGAS Score: Global functioning impairment was considered
moderate (CGAS mean = 48.8; SD = 8.9). There were no
differences concerning global functioning between gender
group (p = 0.699). Adolescents were more impaired than
children (p = 0.038).
3.2. Clinical variables and DS severity
There were no correlation between severity of DS and seizure
control (p = 0.936), age of onset (p = 0.731) and duration of
Table 3




Age of onset 0.731** 0.251**
Duration of epilepsy 0.602** 0.365**
Seizure control 0.936* 0.345*
Polytherapy 0.083* 0.092*
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DS when comparing those with and without hippocampal atrophy
(p = 0.614) or laterality. Impairment of global functioning was not
associated with epilepsy variables (p > 0.05) (Table 3).
4. Discussion
Depression is the most common PD in people with epilepsy.
Although the prevalence of DS was high compared to previous
studies with a heterogeneous group of children with epilepsy, it
was similar to studies that included only children with TLE.20 This
ﬁnding only corroborates the classical concept that epilepsy is a
condition, not one disease, and the study of psychopathology in
epilepsy must take this fact into account.
Another important ﬁnding of this study is the early age of onset
of DS, corroborating previous ﬁndings.14 Children and adolescent
with DS are at higher risk for recurrence of depressive episodes
during their adult years with important psychosocial impact.21–23
For children and adolescents with primary depression, early age of
onset and the severity of DS associated with non-adherence to
treatment or lack of treatment are predictive of recurrence in adult
life.24 It emphasizes the need of a broader approach of epilepsy,
encompassing the treatment of PD.
To the best of our knowledge, this study represents the ﬁrst
assessment on the severity of DS and global functioning in children
and adolescents with TLE. Our results show that most of children
and adolescents with TLE present with DS at moderate to severe
level. Therefore, DS affect children and adolescents early in the
course of their disease. This ﬁnding is a major concern considering
that adolescents with epilepsy and depression are frequently
underdiagnosed and undertreated.11,14,25,26 In addition patients
with TLE may exhibit signiﬁcantly greater risk for lowering of
intervals of episodes of DS indicating a poorer prognosis for these
comorbidities in the context of chronic TLE.27 Therefore, we are
facing a group of high vulnerability to develop recurrence of severe
DS increasing morbidity, co-morbidity with other psychiatric
disorders such as substance abuse and mortality by along their
lives.24,28
There were no differences in DS severity between age and
gender groups. In general, the experience of depression is highly
similar for children and adolescent and for girls and boys with
some developmental differences in the phenomenology of DS with
the increase of the age29 though the prevalence of depressive
disorder is high in female group in adolescents.
The study of Modli et al.30 showed that children diagnosed with
a single seizure or epilepsy have similar clinically signiﬁcant
impairments in quality of life. Questionnaires of quality of life,
although important measures, are subjective measures of how
affected is the patients by its chronic disorder, which not take into
account the misperception of the patient about his own condition
in terms of its limitations for daily activities. For this study, we
used an objective measure of global functioning impairment – theCGAS Score. Global function scale represent an objective measure
of a disease in daily activities, such as school, family, playing with
peers, etc. The lack of correlation between clinical variables and
CGAS Score for global functioning impairment corroborates
previous ﬁndings with quality of life questionnaires in patients
with epilepsy that showed that depression was more important
than seizure frequency.31,32
Children and adolescents with TLE showed a moderate global
functioning impairment. However, adolescents with DS associated
to TLE scored higher in global functioning than children. It is
around adolescence when individuals have more social and
academic activities and are more responsible for daily tasks, in
way adolescents may be more impaired when depressed compared
to children. In adolescence, children achieve the ability to think
abstractly33 leading to a better understanding about the disease
and the impact on life functioning. The sense of lack of control
associate with seizures unpredictability combined with negative
attitudes toward the seizures13 aggravated by cognitive distortion
associated to depression may also lead this youth to be more global
impaired when depressed. In addition, it must be postulated that
the impact of TLE on cognitive functioning, such as memory and
executive function,34,35 reduce both the academic achievements
and the daily life efﬁciency in adolescents and adults36 which may
lead to DS aggravation.
Epilepsy variables were not correlated to the severity of DS.
Studies in adults have reported that DS is more frequent in patients
with MTLE-HS, independent of the lateralization.37,38 Contra-
dicting these ﬁndings, in this study there were no differences in the
severity of DS and global functional impairment between lateral
and mesial temporal lobe epilepsy and between symptomatic and
probably symptomatic group. The existing hypothesis for this age
effect is that chronic excessive neuronal excitatory observed in
MTLE-HS patients may be associated to a worsening DS and
lowering the intervals between depressive episode27 and the
severity of DS along the course of MTLE-HS illness. We hypothe-
sized that in this pediatric series, we are probably evaluating the
ﬁrst manifestation of DS in children with shorter epilepsy duration,
which may be not diagnosed in most of these patients until they
reach adult life and this fact may be one of the reasons. Association
between hippocampal atrophy and severity of DS is still
controversial in studies with adults.39–41 Our results may be
affected by the small sample size in each group. A further study
with larger number of patients is indeed necessary to establish this
association in pediatric population.
In this study, patients with IQ lower than 80 were excluded.
Therefore, we must consider the level of intelligence quotient (IQ)
of our patients, since higher IQ may relate to a higher awareness of
difﬁculties determining depressive symptoms but also to stronger
strategies to handle with the sickness, such as an active
participation and compliance to pharmacological assumption,
reducing the speciﬁc impact of medical variables related to
epilepsy, such as seizure severity.
The main limitations are the study design and the low sample
size. It must be considered that a cross-sectional design, as
performed in our work, may be considered inappropriate to
investigate DS associated to epilepsy. Depressive symptoms in
persons with epilepsy present an intermittent course.42 Therefore,
the severity of DS at one speciﬁc moment may not represent the
real severity level of DS in children and adolescents with TLE when
evaluated with a longitudinal study. Another point to be
considered is the absence of a speciﬁc systematizing instrument
to evaluate DS in interictal period which led us to use instruments
used for DS in general population. Although this was not a
community-based study, the bias generated by studies in a in a
tertiary epilepsy center were partially ruled-out since patients
from primary care centers were included. The small sample size
A. Pereira, K.D. Valente / Seizure 22 (2013) 708–712712implies that the impact of comorbidities such as ADHD and anxiety
cannot be evaluated. By the same token, some aspects of epilepsy
such as the use of Topiramate that may have a negative impact on
DS could not be evaluated in the present study. These associations
remain to be determined in a further study with a larger sample
size.
5. Clinical implications
Our ﬁndings suggest that children and adolescents with TLE
have moderate to severe DS early in the course of their illness with
a relevant impact in their global functional activities, which are
frequently neglected by those in care of these patients. This early
presentation if not diagnosed and treated may put these children
and adolescents with TLE at risk of recurrent depressive episodes,
mortality by and archived poor social, family, work, academic and
affective relationship functioning along their lives. Although there
were no correlation between epilepsy clinical variables and
severity of depressive symptoms and global functioning, more
systematic studies are necessary to determine the clinical features
and course of depressive disorders in children and adolescents
with TLE.
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